Skip to main content

Drug Interactions between AccessPak for HIV PEP Basic and lamivudine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

lamiVUDine emtricitabine

Applies to: lamivudine and AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

GENERALLY AVOID: Concomitant use of the cytidine analog nucleoside reverse transcriptase inhibitors (NRTI) lamivudine and emtricitabine may inhibit the intracellular phosphorylation of one another to their respective active derivative in vivo. This could result in diminished antiretroviral effects of these drugs. However, clinical experience on the coadministration of cytidine analogs is lacking. This interaction may also occur with zalcitabine. In addition, the therapeutic efficacy of these drugs in combination appears limited, since lamivudine and emtricitabine have similar resistance profiles via mutation of the same viral reverse transcriptase gene (M184V).

MANAGEMENT: The use of the cytidine analog NRTIs lamivudine, emtricitabine, or zalcitabine in any combination in an antiretroviral treatment regimen that consists of two NRTIs is not recommended. Local antiretroviral treatment experts should be consulted for current practice.

References (5)
  1. (2001) "Product Information. Epivir (lamivudine)." Glaxo Wellcome
  2. Veal GJ, Hoggard PG, Barry MG, Khoo S, Back DJ (1996) "Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation." AIDS, 10, p. 546-8
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. Cerner Multum, Inc. "Australian Product Information."
  5. Department of Health and Human Services (2015) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultAndAdolescentGL.pdf

Drug and food interactions

Minor

tenofovir food

Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References (1)
  1. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer